2573121-53-4
2573121-53-4
Chemical Structure
Imvotamab
Synonym(s): IGM-2323
- CAS No.: 2573121-53-4
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Imvotamab]
Biological Activity: Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imvotamab | Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hernandez G H, et al. Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies[J]. Blood, 2022, 140(Supplement 1): 6436-6438.
- [2]. Li K, et al. Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile[J]. Blood, 2022, 140(Supplement 1): 6010-6011.
- [3]. Budde E, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class IgM based bispecific antibody Igm-2323 (anti-CD20 x anti-CD3) in patients with advanced B-cell malignancies[J]. Blood, 2020, 136: 45-46.
- [4]. Hart K C, et al. High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing[J]. Cancer Research, 2022, 82(12_Supplement): 4179-4179.
Keywords
